Omnicell (NASDAQ:OMCL) Rating Lowered to Hold at BidaskClub

Omnicell (NASDAQ:OMCL) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Wednesday, March 27th, BidAskClub reports.

Other analysts have also issued reports about the company. Zacks Investment Research lowered Omnicell from a “hold” rating to a “sell” rating in a research report on Monday, March 25th. ValuEngine raised Omnicell from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. Dougherty & Co upped their target price on Omnicell from $78.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, March 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $80.00 target price (up from $70.00) on shares of Omnicell in a report on Thursday, December 6th. One analyst has rated the stock with a sell rating, four have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $76.56.

OMCL traded down $0.29 during midday trading on Wednesday, hitting $71.38. 451,831 shares of the company were exchanged, compared to its average volume of 271,402. The company has a market capitalization of $2.94 billion, a PE ratio of 46.65, a PEG ratio of 3.32 and a beta of 1.23. The company has a current ratio of 1.94, a quick ratio of 1.45 and a debt-to-equity ratio of 0.20. Omnicell has a 1-year low of $42.01 and a 1-year high of $86.87.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, February 7th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.54 by $0.16. Omnicell had a return on equity of 9.31% and a net margin of 4.79%. The company had revenue of $211.75 million for the quarter, compared to the consensus estimate of $215.41 million. During the same period in the previous year, the business earned $0.55 EPS. The firm’s revenue was up 7.8% compared to the same quarter last year. Equities research analysts predict that Omnicell will post 1.83 EPS for the current fiscal year.

In related news, Director Gary S. Petersmeyer sold 750 shares of the stock in a transaction on Tuesday, February 12th. The stock was sold at an average price of $78.87, for a total value of $59,152.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Dan S. Johnston sold 8,210 shares of the stock in a transaction on Monday, April 15th. The shares were sold at an average price of $81.16, for a total value of $666,323.60. Following the completion of the transaction, the executive vice president now directly owns 36,504 shares in the company, valued at approximately $2,962,664.64. The disclosure for this sale can be found here. In the last ninety days, insiders sold 88,982 shares of company stock worth $7,389,181. Insiders own 2.77% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OMCL. Meeder Asset Management Inc. bought a new position in Omnicell in the fourth quarter valued at $35,000. Bronfman E.L. Rothschild L.P. grew its stake in shares of Omnicell by 451.8% during the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 618 shares of the company’s stock valued at $38,000 after buying an additional 506 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Omnicell by 125.0% during the first quarter. Nisa Investment Advisors LLC now owns 540 shares of the company’s stock valued at $44,000 after buying an additional 300 shares during the last quarter. IFP Advisors Inc grew its stake in shares of Omnicell by 109.3% during the fourth quarter. IFP Advisors Inc now owns 741 shares of the company’s stock valued at $45,000 after buying an additional 387 shares during the last quarter. Finally, Financial Gravity Wealth Inc. bought a new position in shares of Omnicell during the first quarter valued at about $50,000. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Company Profile

Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.

Further Reading: What is Cost of Goods Sold (COGS)?

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.